Sign up
Pharma Capital

Neurotech International targets cash injection for neurological solutions

The halt will remain in place until Friday 13th October 2017.
1507677308_australian-cash-2.jpg
The company's shares are in pre-open

Neurotech International Ltd (ASX:NTI) is a medical device and solutions company working on clinical neurotechnology solutions.

The company's flagship device Mente Autism is focused on autism.

Neurotech is now heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare.

The halt will remain in place until the opening of trade on Friday 13th October 2017, or earlier if an announcement is made to the market.



Register here to be notified of future NTI Company articles
View full NTI profile

Neurotech International Ltd Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.